Rebel Medicine is a clinical-stage biotechnology company headquartered in Salt Lake City that develops proprietary drug-delivery technologies to extend the duration of validated active pharmaceutical ingredients. Its lead product, Alevatrix™, is a novel long-acting formulation of bupivacaine encapsulated in the company's injectable matrix designed to release drug at the site of administration for up to 72 hours. In preclinical studies Alevatrix demonstrated prolonged, multi-day non-opioid analgesia with a favorable safety profile. The company has opened an Investigational New Drug (IND) application with the U.S. FDA for Alevatrix and plans a first-in-human, randomized, dose-escalation, active-controlled Phase 2 trial in bunionectomy patients. Rebel is advancing additional pipeline programs that use its delivery systems to provide extended-release of injectable drugs from days to months. The company closed a $6 million Series A to support clinical development and accelerate its opioid-sparing pain therapeutic programs.

Total raised

$6M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2025